Amgen, Inc., has announced a “fast-track” designation for two experimental therapies, AMG 531 and AMG 706. canadian antibiotics

AMG 531, which received orphan drug designation in 2003, represents a new approach to treating immune thrombo-cytopenic purpura (ITP), an autoimmune bleeding disorder. AMG 706 is in phase 2 trials for the treatment of imatinib-resistant gastrointestinal stromal tumors (GISTs), which are fatal.

Random Posts:

• Once-a-Day Beta Blocker Carvedilol (Coreg CR)
• Anticoagulation with Warfarin Safe for Some, Not for Others
• Early Rasagiline for PD
• Long-Term Aspirin, NSAIDs, And Renal Function in Women
• Bevacizumab Beneficial for Non-Small Cell Lung Cancer